Update: HLD-0915 Advances with FDA Fast Track Designation for Metastatic Castration-Resistant Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxTrial to Test If Intermittent Fasting Can Boost Prostate Cancer Treatment Efficacy
/in Clinical Trial, Localized, Metastatic, Phase 1, Phase 2/by MaxPhase 2 trial: Tarlatamab for Neuroendocrine Prostate Cancer (NEPC)
/in Clinical Trial, Metastatic, Phase 2/by MaxPhase Ib/II Study of TYK-00540 Combined With Enzalutamide in mCRPC
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase Ib/II Clinical Trial of TY-302 and Abiraterone Acetate in mCRPC
/in Clinical Trial, Phase 1, Phase 2/by MaxPhase 1/2 Trial for DS-3939a: A Novel TA-MUC1–Directed ADC for Advanced Prostate Cancer and Beyond
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxSummary of the PC-BETS Substudy C: Darolutamide in Biomarker-Selected mCRPC
/in Clinical Trial, Metastatic, Phase 2/by MaxEarly Results of Gedatolisib and Darolutamide in mCRPC Treatment
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 1/2 For a New PARP1 Inhibitor: EIK1004 (IMP1707) For mCRPC
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 50/2025 December 14, 2025
- GSK5764227: An Antibody-Drug Conjugate Targeting B7-H3 Enters Phase 1/2 Trial December 12, 2025
- MHB048C: A New PSMA-Targeted Therapy for Advanced Solid Tumors December 12, 2025
- Logic-gated DARPins, a Promising Advancement in Immune Therapy for Solid Tumors December 11, 2025